

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**OMB APPROVAL**

OMB Number: 3235-0101  
Expires: June 30, 2020  
Estimated average burden  
hours per response ..... 1.00

**FORM 144  
NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933**

SEC USE ONLY  
DOCUMENT SEQUENCE NO.

**ATTENTION:** *Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker.*

CUSIP NUMBER

1 (a) NAME OF ISSUER <i>(Please type or print)</i> <b>TFF Pharmaceuticals, Inc.</b>		(b) IRS IDENT. NO. <b>82-4344737</b>	(c) S.E.C. FILE NO. <b>001-39102</b>	WORK LOCATION
1 (d) ADDRESS OF ISSUER		STREET	CITY	STATE
<b>3801 S. Capital of Texas Hwy, Suite 330 Austin, Texas, 78704</b>				ZIP CODE
		(e) TELEPHONE NO.		
		AREA CODE	NUMBER	
		<b>737</b>	<b>802-1973</b>	
2 (a) NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES ARE TO BE SOLD <b>Lung Therapeutics, Inc.</b>		RELATIONSHIP TO ISSUER <b>Stockholder (1)</b>	(c) ADDRESS STREET CITY STATE ZIP CODE <b>3801 S. Capital of Texas Hwy, Suite 330 Austin, Texas, 78704</b>	

*INSTRUCTION: The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the S.E.C. File Number.*

3 (a) Title of the Class of Securities To Be Sold	(b) Name and Address of Each Broker Through Whom the Securities are to be Offered or Each Market Maker who is Acquiring the Securities	SEC USE ONLY	(c) Number of Shares or Other Units To Be Sold <i>(See instr. 3(c))</i>	(d) Aggregate Market Value <i>(See instr. 3(d))</i>	(e) Number of Shares or Other Units Outstanding <i>(See instr. 3(e))</i>	(f) Approximate Date of Sale <i>(See instr. 3(f))</i> (MO. DAY YR.)	(g) Name of Each Securities Exchange <i>(See instr. 3(g))</i>
		Broker-Dealer File Number					
Common stock: Par value \$0.001	Jefferies LLC 520 Madison Avenue New York, NY 10022		962,000 pursuant to a variable price forward sales contract (2)	\$8,821,540 (3)	25,371,781(4)	01/03/22 (2)	Nasdaq

**INSTRUCTIONS:**

1. (a) Name of issuer
- (b) Issuer's I.R.S. Identification Number
- (c) Issuer's S.E.C. file number, if any

- 3 . (a) Title of the class of securities to be sold
- (b) Name and address of each broker through whom the securities are intended to be sold
- (c) Number of shares or other units to be sold (if debt securities, give the aggregate face amount)
- (d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to the filing of this notice



- (d) Issuer's address, including zip code
- (e) Issuer's telephone number, including area code
- ( )
- 2. (a) Name of person for whose account the securities are to be sold
- (b) Such person's relationship to the issuer (e.g., officer, director, 10% stockholder, or member of immediate family of any of the foregoing)
- (c) Such person's address, including zip code
- (e) Number of shares or other units of the class outstanding, or if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer
- Approximate date on which the securities are to be sold
- (g) Name of each securities exchange, if any, on which the securities are intended to be sold

**Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1147 (08-0



**TABLE I — SECURITIES TO BE SOLD**

*Furnish the following information with respect to the acquisition of the securities to be sold  
and with respect to the payment of all or any part of the purchase price or other consideration therefor:*

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired (If gift, also give date donor acquired)	Amount of Securities Acquired	Date of Payment	Nature of Payment

**INSTRUCTIONS:** If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

**TABLE II — SECURITIES SOLD DURING THE PAST 3 MONTHS**

*Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.*

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds

**REMARKS:**

- (1) The filing of this Form 144 shall not be construed as an admission that the undersigned is an affiliate of the issuer.
- (2) In accordance with the procedures described in the interpretive letters from the staff of the Securities and Exchange Commission to Goldman Sachs & Co., dated December 20, 1999, and to Bank of America, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated, dated December 1, 2011, on the date hereof, Lung Therapeutics, Inc. entered into a post-paid forward sale of 962,000 shares of common stock of TFF Pharmaceuticals, Inc. (such number of common stock, the "Shares") to an unaffiliated financial institution at a price based on the volume weighted average price of the Shares over a period of time as determined by the financial institution, subject to an agreed minimum and maximum period.
- (3) Aggregate Market Value of the Shares calculated based on a closing per share price of \$9.17 on January 3, 2022.
- (4) The number of shares of Issuer's common stock outstanding as of November 11, 2021 as reported on the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021.



**INSTRUCTIONS:**

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

01/03/22

01/03/22

DATE OF NOTICE

DATE OF PLAN ADOPTION OR GIVING OF INSTRUCTION,

IF RELYING ON RULE 10B5-1

**ATTENTION:** *The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.*



(SIGNATURE)

*The notice shall be signed by the person for whose account the securities are to be sold. At least one copy*

*of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.*

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**

SEC 1147 (02-08)